Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient

Nephron

Volumn 73, Issue 4, 1996, Pages 736-

  Panuccio, Vincenzo ^a   Enia, Giuseppe ^a   Parlongo, Saverio ^a   Cutrupi, Sebastiano ^a   Zoccoli, Carmine ^a  

^a CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; FIBRIC ACID DERIVATIVE; MYOGLOBIN; SIMVASTATIN;

ADULT; CASE REPORT; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; FEMALE; HUMAN; HYPERLIPIDEMIA; LETTER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ANTILIPEMIC AGENTS; BEZAFIBRATE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; POLYCYSTIC KIDNEY DISEASES; RHABDOMYOLYSIS;

EID: 0029737007     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189184     Document Type: Article

References (3)

1. Brown MS. Goldstein JL: Drug used in the treatment of hyperlipoproteinemias; in Good-man-Gilman A (ed): The Pharmacological Basis ofThcrapeutics. ed 8. New York, Pergamon Press, 1990. pp 874-896.
2. Piérides AM. Alvarez-Ude F. Kerr DNS, Skill-en AW: clofibrate-induced muscle damage in patients with chronic renal failure. Lancet 1975:ii: 1279-1282.
3. Chan MK: Sustaincd-rclcasc bczafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis. Nephron 1990;56:56-61.